Key Takeaways
- • The American Investment Council released a video series documenting private equity's role in life sciences, featuring KKR-backed Headlands Research, a clinical trial sites network based in Portland, Oregon that emphasizes scientific rigor, data quality, and patient population diversity.
- • Private equity has deployed $280 billion across more than 1,800 life sciences and medical device companies in the U.S. over the past decade, according to an AIC and Pitchbook report released in March 2022.
- • Headlands Research CEO Mark Blumling attributed the company's growth trajectory directly to private equity capital and institutional resources, stating the firm "wouldn't be where it is right now without the benefit of private equity, both from a capital perspective, but also just the resources and knowledge to build and grow."
- • The video initiative demonstrates private equity's expanding focus on clinical trial infrastructure modernization and the broader life sciences ecosystem as a growth investment thesis in the post-pandemic period.
Summary
The American Investment Council released the first installment of a video series on March 30, 2022, highlighting private equity's investment strategy in the life sciences sector. The featured company, Headlands Research, operates a network of clinical trial sites and is backed by KKR-managed funds. The video documents how Headlands is reshaping clinical trial operations by prioritizing scientific rigor, data quality, and diversity among patient populations—reflecting operational improvements funded and supported through private equity capital and expertise.
Mark Blumling, CEO of Headlands Research, characterized the company's development as fundamentally dependent on private equity backing. Beyond capital infusion, Blumling emphasized the value of institutional resources and operational knowledge that KKR provided, enabling the firm to build and scale its clinical trial infrastructure. This executive perspective underscores a broader institutional narrative: that private equity brings not only funding but also strategic operational capabilities to emerging life sciences businesses.
The timing of the video release coincided with publication of a research report co-authored by the American Investment Council and Pitchbook titled "Improving Medical Technologies: Private Equity's Role in Life Sciences." The report quantifies private equity's impact: over the past decade, private equity investors have committed $280 billion across more than 1,800 life sciences and medical device companies throughout the U.S. This capital deployment reflects growing institutional appetite for life sciences infrastructure and medical technology development as a defensive, revenue-stable alternative investment strategy.
Drew Maloney, President and CEO of the American Investment Council, collaborated with Blumling on a Punchbowl News event to underscore private equity's role in supporting small business and community economic development during the post-pandemic recovery period. The video series itself represents an industry advocacy effort designed to educate institutional audiences on private equity's functional contributions to healthcare innovation and clinical research advancement—a strategic communications initiative positioning the asset class as aligned with public health outcomes and scientific progress.
Mark Blumling, CEO of Headlands Research, characterized the company's development as fundamentally dependent on private equity backing. Beyond capital infusion, Blumling emphasized the value of institutional resources and operational knowledge that KKR provided, enabling the firm to build and scale its clinical trial infrastructure. This executive perspective underscores a broader institutional narrative: that private equity brings not only funding but also strategic operational capabilities to emerging life sciences businesses.
The timing of the video release coincided with publication of a research report co-authored by the American Investment Council and Pitchbook titled "Improving Medical Technologies: Private Equity's Role in Life Sciences." The report quantifies private equity's impact: over the past decade, private equity investors have committed $280 billion across more than 1,800 life sciences and medical device companies throughout the U.S. This capital deployment reflects growing institutional appetite for life sciences infrastructure and medical technology development as a defensive, revenue-stable alternative investment strategy.
Drew Maloney, President and CEO of the American Investment Council, collaborated with Blumling on a Punchbowl News event to underscore private equity's role in supporting small business and community economic development during the post-pandemic recovery period. The video series itself represents an industry advocacy effort designed to educate institutional audiences on private equity's functional contributions to healthcare innovation and clinical research advancement—a strategic communications initiative positioning the asset class as aligned with public health outcomes and scientific progress.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.